Literature DB >> 19382090

[Pathogenesis and treatment of vascular calcification in CKD].

D Brancaccio1, M Gallieni, S Pasho, G Fallabrino, L Olivi, E Volpi, P Ciceri, E Missaglia, C Ronga, C Brambilla, A Butti, L Rocca-Rey, G Chiarelli, M Cozzolino.   

Abstract

Increased vascular calcification is a major cause of cardiovascular events in patients with chronic kidney disease (CKD). It is the result of an active ossification process counteracted by ''bone'' proteins such as osteopontin, alkaline phosphatase, osteoprotegerin, and osteocalcin. Chronic kidney disease - mineral and bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism that occurs in CKD. In addition to abnormalities in the serum calcium and phosphate profile, CKD-MBD is characterized by abnormalities of bone turnover, mineralization, volume and growth as well as vascular calcification. Considering that the presence and extent of vascular calcification in CKD portend a poor prognosis, many efforts have been made to shed light on this complicated phenomenon to prevent vascular calcium deposition and its progression. Indeed, careful control of calcium load, serum phosphate and parathyroid hormone along with the use of calcium-free phosphate binders and vitamin D receptor activators represent a new therapeutic armamentarium to improve quality of life and reduce mortality in CKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19382090

Source DB:  PubMed          Journal:  G Ital Nefrol        ISSN: 0393-5590


  2 in total

1.  Chronic kidney disease is associated with increased coronary artery atherosclerosis as revealed by multidetector computed tomographic angiography.

Authors:  Sion K Roy; Albert Cespedes; Dong Li; Tae-young Choi; Matthew J Budoff
Journal:  Tex Heart Inst J       Date:  2012

2.  Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease.

Authors:  Simona Mihai; Elena Codrici; Ionela Daniela Popescu; Ana-Maria Enciu; Elena Rusu; Diana Zilisteanu; Radu Albulescu; Gabriela Anton; Cristiana Tanase
Journal:  Dis Markers       Date:  2016-09-07       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.